Target
$21.39 → $21.41
Current stock research snapshot · 8/22/26 Fresh
FTREFortrea
Investment conviction●●○○○2 of 5 · current snapshot
Research target$21.41Current stock price target
Investment thesis statusINTACTLast reviewed 8/22/26
Market cap1.63BSnapshot value · 8/22/26
Research history
See all FTRE changes ↗What changed
Thesis status
WEAKENED → INTACT
Last reviewed
7/8/26 → 8/22/26
Full-service CRO, spun from Labcorp. Turnaround story — lower margin, smaller scale than IQV/ICLR/MEDP. Higher risk, higher potential upside.
Turnaround execution under independent management; biotech funding recovery; FSP model adoption; potential M&A target in consolidating CRO market.
Turnaround execution risk; smaller scale creates competitive disadvantage vs IQV/ICLR; margin pressure; Labcorp spin-off overhang.
Bullish — Barclays raised PT to $18 from $16 (Overweight) noted in late June/early July watchlists [X search Aug 2026]
Snapshot · 8/22/26🟡 Mixed · ins-$4.4M · 13F 17+/7-×0.5 · short↑0.34
Snapshot · 8/22/26